Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 575 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04993885RecruitingPhase 2
Avatrombopag for adults with immune low platelets
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04600960RecruitingPhase 2
Eltrombopag to raise low platelets after chemotherapy
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04890041Recruiting
Testing TPO medicines for immune low platelets in teens
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT05199909RecruitingPhase 2
Testing zanubrutinib for antiphospholipid syndrome with low platelets
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05236582RecruitingPhase 2
Herombopag for low platelets from chemotherapy side effects
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05214391RecruitingPhase 2
Zanubrutinib for chronic immune low platelets after prior treatments
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05641610RecruitingPhase 1/Phase 2
Study drug for adults with hemophilia B who still bleed
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05630651Recruiting
ZS801 for adults with severe hemophilia B
This trial studies ZS801, a gene therapy, in adults with hemophilia B who have very low natural FIX (a clotting protein) and frequent bleeding or joint problems. It aims to see how well it works and whether it is safe, especially by monitoring blood counts, infections, and immune responses.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05888870RecruitingPhase 4
Testing a treatment for hemophilia A with inhibitor antibodies
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
TianjinAges 14–65 - NCT06281327RecruitingPhase 2
Avatrombopag for children with ITP switching from eltrombopag
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
TianjinAges 6–18 - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT07374874Recruiting
Heart and nervous system health after stem cell transplant
This study looks at how your autonomic nervous system (the part that controls heartbeat and digestion) affects the risk of graft-versus-host disease (a condition where donor cells attack your body) after a half-matched stem cell transplant. You may be able to join if you are older than 16 and receiving a half-matched transplant from a family donor.
Tianjin, Tianjin MunicipalityAges 16 years+ - NCT07372690Recruiting
Personalized goal setting for stem cell transplant recovery
This trial looks at whether a personalized goal-setting tool helps children and teens recovering from a stem cell transplant. It is designed for young patients with cancer or blood disorders who are not already in rehab.
Torino, TOAges 6 months–17 years - NCT07362199RecruitingPhase 2
New combo treatment for chronic ITP
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07362238RecruitingPhase 2
Daratumumab vs Rituximab for pediatric ITP
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
TianjinAges 6–18 - NCT07358195RecruitingEarly Phase 1
Combined stem cell and kidney transplant from a relative
This trial tests a combined transplant of blood-forming stem cells and a kidney from the same family member. It aims to help people with both advanced kidney failure and a blood cancer by potentially reducing the need for lifelong anti-rejection medicines.
Boston, MassachusettsAges 18–70 - NCT06857604Recruiting
Immune defects behind common blood diseases in young people
This study looks at how problems with the immune system might be linked to certain blood disorders in people under 25. The goal is to better understand what causes these conditions and find better ways to treat them.
Montreal, CanadaAges Up to 25 years - NCT07349849RecruitingEarly Phase 1
mRNA Drug Targeting CD19 for Blood Cancers
This study tests a new mRNA-based medicine that targets CD19 on cancer cells. It is for people with B-cell lymphoma or leukemia who have run out of standard treatment options.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07338604RecruitingEarly Phase 1
UTAA07 cell therapy for relapsed CD7+ blood cancers
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
Suzhou, JiangsuAges 18 years+ - NCT07341815Recruiting
Support for parents with cancer and their children
This trial offers a talking support program to help parents with advanced cancer communicate better with their children aged 10 to 25. It focuses on open conversations about the illness and its impact on family life.
AnderlechtAges 18 years+ - NCT04956133Recruiting
Physical activity program for kids during cancer treatment
This trial tests whether a structured physical activity program can help children and teens feel better and stay active during cancer treatment or shortly after. It involves the child and a parent/caregiver for safety during sessions.
Calgary, AlbertaAges 5–18 - NCT07315893Recruiting
Closing stomach defects with a stitching device
This trial tests a special stitching tool to close holes in the stomach after removing abnormal growths. It may help patients heal better after a routine procedure to remove suspicious tissue.
Tel AvivAges 18 years+ - NCT07313059Recruiting
Clonal hematopoiesis study for people 55+
This study looks at a condition called clonal hematopoiesis (CH), where some blood cells have changes that may affect their health. It aims to prevent, treat, and better understand CH. You may qualify if you are 55 or older and have low blood counts that persist over time.
Canberra, Australian Capital TerritoryAges 55 years+
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 575 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.